Mirvetuximab soravtansine

索米妥昔单抗

Report date: 2026/05/28 20:00:21
First In Class

Base Information

Drug NameMirvetuximab soravtansine
Drug Alias Namemirvetuximab soravtansina索米妥昔单抗索星-米妥昔单抗Anti-FOLR1 monoclonal antibody-maytansinoid conjugate IMGN853mirvetuximabum soravtansinum +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionFolate receptor alpha antagonistsTubulin inhibitors
TargetsFolate receptor alphaTubulin
Therapy Area/IndicationsSolid tumoursFallopian Tube DiseasesEndometrial Neoplasms +[14] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Approved Indications in ChinaFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Original Approved Country/TerritoryUnited States
Original Approved Date2022/11/14
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesImmunogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteNational Cancer InstituteImmunogen Inc +[9] 
Inactive CompaniesDuke UniversityThe University Of OklahomaThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsSolid tumoursFallopian Tube DiseasesEndometrial Neoplasms +[12] 
Inactive IndicationsAdenocarcinoma, Clear CellNeoplasms

Other Information

ATC CodeL01FX
Related LinksWikipediaDrugBankKEGG